Stewart J W, Quitkin F M, Liebowitz M R, McGrath P J, Harrison W M, Klein D F
Arch Gen Psychiatry. 1983 Feb;40(2):202-7. doi: 10.1001/archpsyc.1983.01790020100010.
The efficacy of desipramine for mild depression was tested in a double-blind, placebo-controlled study of outpatients with scores below 19 on the Hamilton Rating Scale for Depression (HAM-D). Of 103 such patients, 23 dropped out and 16 improved during a ten-day placebo period. Among 64 patients completing the randomized portion of the study, significantly more improved with desipramine that with placebo. The Research Diagnostic Criteria (RDC) category of major depressive disorder largely accounted for the drug-placebo response difference found for the entire sample. Patients with intermittent depressive disorder improved significantly less frequently with desipramine than patients with major depressive disorder. Independent of RDC diagnosis, severity of illness correlated with outcome. Thus, patients with pretreatment HAM-D scores at or above the median demonstrated significant drug effect, while patients with lower pretreatment HAM-D scores did not.
在一项针对汉密尔顿抑郁量表（HAM-D）评分低于19分的门诊患者的双盲、安慰剂对照研究中，测试了去甲丙咪嗪对轻度抑郁症的疗效。在103名此类患者中，有23人退出研究，16人在为期十天的安慰剂治疗期内病情有所改善。在完成研究随机分组部分的64名患者中，服用去甲丙咪嗪后病情改善的患者明显多于服用安慰剂的患者。研究诊断标准（RDC）中的重度抑郁症类别在很大程度上解释了整个样本中药物与安慰剂反应的差异。间歇性抑郁症患者服用去甲丙咪嗪后病情改善的频率明显低于重度抑郁症患者。与RDC诊断无关，疾病严重程度与治疗结果相关。因此，治疗前HAM-D评分处于或高于中位数的患者显示出显著的药物疗效，而治疗前HAM-D评分较低的患者则未显示出药物疗效。
